Rivaroxaban

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

999 PubMed studies analyzed · 331 RCTs · Evidence Score: 72.3

Research Domains

Rivaroxaban has been studied across 13 research domains including ❤️ Cardiovascular, 🫁 Respiratory, 🔬 Oncology, 🫘 Kidney, 😴 Sleep. The primary research focus is ❤️ Cardiovascular with 81% of studies addressing this area.

Loading evidence profile...

This evidence profile for Rivaroxaban is generated deterministically from 999 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.